Zafgen endocrine/metabolic news

Zafgen will reduce headcount by 47 (34%) to 31 and discontinue development of beloranib ( ZGN-440) to focus on developing ZGN-1061 to treat severe and complicated obesity. The cuts include

Read the full 305 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE